However, EGFR‐mutation‐positive and ALK‐rearrangement‐positive NSCLC patients with poor PS often benefit from treatment with EGFR tyrosine kinase inhibitors (EGFR‐TKIs) and ALK tyrosine kinase inhibitors (ALK‐TKIs), which provide high activity with acceptable toxicity levels in patients with poor PS.2, 3. Here, ALK is linked to non-small cell lung carcinoma.